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Cancer cachexia, a syndrome characterized by profound body
wasting due to a persistently negative nitrogen balance, is an
important cause of death among cancer patients and still defies an
effective management (Calman, 1992; Tisdale, 1997). Different
mechanisms, often in combination, are involved in its patho-
genesis, including metabolic competition for nutrients between
tumour and host tissues or protein-calorie malnutrition, but a
prominent role is played by circulating mediators and hormonal
perturbations (Tessitore et al, 1993a; Soeter and Baracos, 1999;
Costelli and Baccino, 2000). The net protein loss is particularly
conspicuous in the skeletal muscle and heart and has been shown
to result from enhanced protein degradation in various clinical or
experimental situations (Kien and Camitta, 1983; Kien and
Camitta, 1987; Tessitore et al, 1987; Melville et al, 1990; Beck
et al, 1991; Tessitore et al, 1993b; Temparis et al, 1994; Baracos et
al, 1995). 
The machinery involved in this muscle protein waste has not
been fully elucidated yet. Not only the precise role of the different
proteolytic systems still has to be assessed, but there is little in-
formation as to how the catabolic signals are transduced into
enhanced tissue protein breakdown. There is evidence that the
ATP-ubiquitin-dependent pathway plays a major role in the accel-
erated muscle proteolysis, both in experimental models of cancer
cachexia and in cancer patients (Temparis et al, 1994; Baracos
et al, 1995; Llovera et al, 1995; Williams et al, 1999a; Bossola M
et al, unpublished observations), although how activation of this
proteolytic system is triggered is not known. By contrast, in spite
of reports of increased lysosomal cathepsin levels (Lundholm et al,
1980; Tessitore et al, 1993b), there is evidence to deny a role for
the lysosomal proteolytic pathway, since protein breakdown in
muscles isolated from tumour-bearing rats was not affected by the
use of appropriate inhibitors (Temparis et al, 1994; Baracos et al,
1995; Llovera et al, 1995). 
As to the Ca2+-dependent proteolytic system, little information
is available at present. On one hand, m-calpain mRNA was found
increased in the muscles of AH-130 Yoshida tumour-bearing rats
(Temparis et al, 1994). On the other, decreasing the intracellular
Ca2+ concentration ([Ca2+]i) or adding thiol proteinase inhibitors
did not affect overall protein degradation rates in muscle prepara-
tions from these animals (Temparis et al, 1994; Baracos et al,
1995; Llovera et al, 1995). However, since the Ca2+-dependent
proteolytic system is thought to be involved in the cleavage of
specific protein targets rather than in bulk protein degradation the
latter observations do not necessarily rule out an activation of the
calpain system. 
A general difficulty encountered in studies on Ca2+-dependent
proteolysis is that calpain activity assays do not provide a measure
of the actual enzyme activity in vivo. Nor are the levels of calpain
mRNA or protein informative in this regard. In such studies,
however, advantage can be taken of the fact that calpain activa-
tion in vivo directly results in cleavage of specific intracellular
substrate proteins (Salamino et al, 1994a; Nath et al, 1996;
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Carafoli and Molinari, 1998). Measuring the time-course of
changes in substrate levels may thus provide an estimate of the
calpain activity in vivo cumulated over time. In the present work
we adopted this approach and selected two independent reporter
substrates, namely, calpastatin, the endogenous calpain inhibitor
that is cleaved by calpain itself (Pontremoli et al, 1991), and the
130 kDa Ca2+-ATPase associated with the plasma membrane
(Salamino et al, 1992, 1994b). As an internal control for the latter
substrate, we also measured the levels of the sarcoplasmic 90 kDa
ATPase, which is resistant to proteolysis by calpain (Yoshida et al,
1990). Moreover, we also assayed tissues for calpain activity in
vitro, thus obtaining an evaluation of the actual enzyme levels as
well as of the calpain/calpastatin balance. 
The data show that both calpastatin and 130 kDa Ca2+-ATPase
levels decreased in the gastrocnemius and heart of rats soon after
implantation of the AH-130 Yoshida ascites hepatoma, while
calpain activity did not significantly change. Loss of calpain
substrates and increased calpain/calpastatin ratio both are strongly
suggestive for an activation of Ca2+-dependent proteolysis in these
tissues. 
MATERIALS AND METHODS 
The experiments were performed on male Wistar rats weighing
about 150 g (Charles River, Como, Italy), housed and cared for in
compliance with the Italian Ministry of Health Guidelines and
with the Principles of Laboratory Animal Care (NIH n. 85–23,
revised 1985). The animals were fed ad libitum on a chow diet
(Piccioni, Brescia, Italy) and had free access to drinking water.
They were divided into 2 groups, namely controls and tumour
bearers: the latter received an intraperitoneal injection of about 108
Yoshida AH-130 ascites hepatoma cells in 2 ml of sterile 0.9%
NaCl, the former a comparable volume of saline. The animals
were sacrificed under light ether anaesthesia 2, 4 or 6 days after
tumour transplantation. Gastrocnemius muscle and heart were
rapidly excised, weighed, frozen in liquid nitrogen and stored at
–80˚C. 
Isolation of calpastatin and calpain 
Hearts or gastrocnemius muscles (4 g) were minced, suspended in
5 volumes (w/v) of cold 0.25 M sucrose containing 0.5 mM 
b-mercaptoethanol and 1 mM EDTA, homogenized in a Waring
Blendor homogenizer set at half-maximal speed (5 bursts of 15 s
each), sonicated (4 bursts of 15 s each), and centrifuged at 100 000 g
for 15 min. To isolate calpastatin, the supernatant was dialysed
against 50 mM Na acetate/acetic acid buffer, pH 6.7, containing
0.1 mM EDTA and 0.5 mM b-mercaptoethanol. The samples were
then separately loaded on a DE32 column (1 ´ 10 cm) equilibrated
in the dialysis buffer, and proteins eluted with 200 ml of a linear
0–0.35 M NaCl gradient (Pontremoli et al, 1991; Salamino et al,
1994a). To isolate calpain, the supernatant was dialysed against
50 mM Na borate/boric acid buffer, pH 7.5, containing 0.1 mM
EDTA, and 0.5 mM b-mercaptoethanol. NaCl was then added to a
0.3 M final concentration and the samples separately loaded on a
Phenyl Sepharose CL-4B column (1 ´ 4 cm) equilibrated in the
dialysis buffer with 0.3 M NaCl added. Calpain activity was eluted
with 20 ml of the same buffer without NaCl in 1 ml fractions
(Pontremoli et al, 1991; Salamino et al 1994). 
Calpain, calpastatin, and Ca2+-ATPase activities 
Calpastatin was assayed on aliquots (150 ml) of the fractions
eluted from the DE32 column, heated at 90˚C for 3 min in order to
inactivate any endogenous protease activity. The activity of
calpastatin was determined using human erythrocyte calpain, the
calpain isoform most sensitive to calpastatin inhibition, and using
acid-denaturated bovine globin as substrate (Salamino et al,
1994a). By ion-exchange chromatography, calpastatin is resolved
into 2 activity peaks that have been previously identified as due to
2 forms generated by post-translational modifications of the same
molecule and named calpastatins I and II according to the elution
order: the first is a non-phosphorylated form that is more active on
m-calpain, the second a phosphorylated form more active on m-
calpain (Pontremoli et al, 1992). Since the changes reproduced
precisely the same pattern for both calpastatins (not shown), data
are presented as the sum of their activities. 
Calpain activity was assayed on aliquots (100 ml) of the frac-
tions eluted from the Phenyl Sepharose column. One unit of
calpastatin activity is the amount required to inhibit one
unit of calpain, the latter being defined as the amount that releases
1 mmol h–1 of free a-amino groups under the conditions specified
(Salamino et al, 1994a). 
Ca2+-ATPase activity in cell membranes isolated from heart or
gastrocnemius muscle was determined as previously reported
(Niggli et al, 1979). After SDS-polyacrylamide gel electrophoresis
and autoradiography, 2 bands were detected: a protein with an Mr
of about 130 kDa, identified as the plasma membrane Ca2+-
ATPase (De Smedt et al, 1991), and a second band with an Mr of
about 90 kDa corresponding to the sarcoplasmic reticulum Ca2+-
ATPase (Yoshida et al, 1990). 
RESULTS 
Since day 2 after inoculation into rats, the Yoshida AH-130 ascites
hepatoma elicited a rapid and progressive weight loss in both the
gastrocnemius muscle and heart, down to 60% of controls (Figure 1),
as previously reported (Tessitore et al, 1987, 1993b). We analysed
these tissues for parameters adequate to provide an evaluation of
the status of Ca2+-dependent proteolysis, as discussed earlier.
The activity of calpains reflects the balance between enzyme
levels and levels of calpastatins, their specific natural inhibitors
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Figure 1 Gastrocnemius muscle (l) and heart (O) wet weight. Data are
expressed as percentages of control values. Significance of the differences:
a = P < 0.05, b = P < 0.01, c = P < 0.001 948 P Costelli et al 
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(Salamino et al, 1992). Activation of calpains proceeds from an
increase of [Ca2+]i through the cleavage of calpastatins, resulting in
the release of active enzyme from the inactive complex. This basic
regulatory mechanism permits the activity of the calpain system to
be promptly tuned in response to manipulations or extracellular
signals that elevate the [Ca2+]i. As a relevant example, decreased
(50–90%) calpastatin levels have been observed in red blood cells
from patients affected by essential hypertension (Pontremoli et al,
1988) or from genetically hypertensive rats of the Milan strain
(Pontremoli et al, 1986); in these erythrocytes the plasma
membrane Ca2+-ATPase is very rapidly degraded in response to
increases in [Ca2+]i. In the present work, total calpain and calpas-
tatin activities were assayed in the gastrocnemius at increasing
times after tumour implantation. As Figure 2 shows, while calpain
activity remained virtually unchanged over the whole length of the
experimental time, calpastatin activity showed a progressive,
substantial decrease down to about 20% of the control value on
day 6. Consequently, the calpain/calpastatin ratio became increas-
ingly unbalanced, reaching a 4-fold elevation at day 6. 
The above data at least indicate that in the gastrocnemius of
tumour-bearing animals the setting of Ca2+-dependent pro-
teolytic system was being shifted in such a way as to favour its
activity. Moreover, since calpastatin itself is a specific calpain
substrate in vivo (Pontremoli et al, 1991), its decrease also
suggests that in this muscle there was an ongoing activation of
the calpain system. To substantiate this inference, in the muscle
of tumour-bearing animals we also measured how changed the
level of the 130 kDa plasma-membrane Ca2+-ATPase, another
yet unrelated calpain substrate, and compared it to the level of
the sarcoplasmic 90 kDa Ca2+-ATPase, which has been reported
to be resistant to calpain proteolysis (Yoshida et al, 1990). The
results in Figure 3 indicate that, while the levels of 90 kDa Ca2+-
ATPase virtually did not change in the gastrocnemius after
tumour implantation, those of the 130 kDa form, in spite of
some fluctuations, decreased down to 79% of the control values
at day 6. Altogether, therefore, the present data consistently
support the possibility that Ca2+-dependent proteolysis was activ-
ated in the gastrocnemius soon after transplantation of the AH-
130 ascites hepatoma in rats. 
Similar results were obtained for the heart, although calpain
activity was not assayed in this tissue. The activity levels of both
calpain substrates, calpastatin (Figure 4) and 130 kDa Ca2+-
ATPase (Figure 3), progressively and substantially decreased in
the heart of tumour-bearers, respectively down to 52% and 61% of
control values at day 6, while those of the 90 kDa Ca2+-ATPase did
not change (Figure 3). Therefore, the inference that in these
animals the Ca2+-dependent proteolysis likely was activated also in
the cardiac muscle appears justified. 
DISCUSSION 
The present findings provide circumstantial yet quite compelling
evidence that, in the present model, the calpain system be-
came activated in both the skeletal and the cardiac muscles of
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Figure 2 Calpain and calpastatin activities and their ratio in gastrocnemius
muscle. Data (U/total tissue) are expressed as percentages of controls.
Calpain specific activity ranged from 0.171 U mg–1 protein at day 0 to
0.216 U mg–1 protein at day 6, capastatin specific activity from 239 U mg–1
protein at day 0 to 74 U mg–1 protein at day 6 after tumour transplantation 
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Figure 3 Activities of 90 kDa Ca2+-ATPase (A, B) and 130 kDa Ca2+-
ATPase (C, D) in the gastrocnemius muscle and heart. (A): r = 0.402, 
P = 0.598; (B): r = 0.540, P = 0.456; (C): r = 0.966, P = 0.034; (D): r = 0.428,
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tumour-bearing animals early during the development of cachexia.
This conclusion is supported by 2 basic observations: (i) the
marked, progressive elevation, in the gastrocnemius at least, of the
calpain/calpastatin ratio which concurs in determining the pace of
Ca2+-dependent proteolysis in vivo; (ii) the progressive decrease in
the activity levels of two specific calpain substrates such as cal-
pastatin itself and the 130 kDa plasma-membrane Ca2+-ATPase,
which likely is the result of calpain activation. Noteworthily,
decreased levels of the 130 kDa Ca2+-ATPase may contribute to
the maintenance of a [Ca2+]i elevation (Vezzoli et al, 1985) and
thus to calpain activation. 
The increase of proteolytic rates in muscle preparations from
tumour-bearing animals has been previously reported (Temparis
et al, 1994; Baracos et al, 1995; Llovera et al, 1995) to be
suppressed neither by the addition of exogenous calpain
inhibitors nor by decreasing the [Ca2+]i. This is not in conflict
with the present conclusion since, by all available evidence,
calpains do not contribute significantly to bulk protein degrada-
tion. Rather, the notion that calpains play a role in the activation
of signal transduction pathways (Melloni et al, 1986; Hirai et al,
1991; Watt and Molloy, 1993; Liu et al, 1996) may provide useful
perspectives for a better understanding of the mechanisms by
which the extracellular signals acting on the muscle (Soeter and
Baracos, 1999; Costelli and Baccino, 2000) drive the elevation of
protein breakdown responsible for tissue waste in cancer
cachexia. In this regard, we cannot exclude that activation of
Ca2+-dependent proteolysis might even precede bulk protein
hypercatabolism and play a causative role in establishing this
metabolic response. Although quite speculative so far, the latter
hypothesis may be consistent with the report that the release of
myofilament proteins from the skeletal muscle in sepsis is likely
associated with activation of Ca2+-dependent proteolysis
(Williams et al, 1999b), while activation of the ATP-ubiquitin-
dependent proteolytic system would be the consequence of an
increased availability of substrates rather than the primary cause
of muscle protein breakdown (Williams et al, 1999b). Finally, the
recent report (Busquets et al, 2000) that the expression of the
muscle-specific calpain p94 is significantly reduced may also be
relevant to the present findings. The loss of function of this particu-
lar calpain is responsible for limb girdle muscular dystrophy type
2A (Richard et al, 1995) and a suggested function of this enzyme
is to protect some muscle proteins from degradation by ubiqui-
tous m-and m-calpains (Kinbara et al, 1998). 
As a final remark, tumour necrosis factor (TNF) is an important
mediator of cachexia in AH-130 tumour-bearing rats (Costelli
et al, 1993; Tessitore et al, 1993a; Llovera et al, 1996) and in other
situations. A reported effect of this cytokine, on some cell types at
least, is to cause [Ca2+]i elevations (Bick et al, 1997; Furukawa and
Mattson, 1998), which, in the light of the present observations,
might well have a role in activating the Ca2+-dependent proteo-
lysis. Furthermore, calpains have been shown to degrade transcrip-
tion factors such as AP-1 and NF-kB (Hirai et al, 1991; Watt and
Molloy, 1993; Liu et al, 1996) which are known to play a protect-
ive role against TNF-induced cell and tissue damage (Das et al,
1995; Jones et al, 1997); thus activation of the Ca2+-dependent
proteolysis might directly involve an attenuation of cell defences
against the cytotoxic action of TNF. Therefore, the present obser-
vations provide new directions for future work aimed at elucid-
ating the mechanisms underlying muscle protein waste in cancer
cachexia. 
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